Uptake and degradation of rat and human very low density (remnant) apolipoprotein by parenchymal and non-parenchymal rat liver cells.
1. The relative contribution of parenchymal and non-parenchymal cells to the in vivo hepatic uptake of serum apolipoproteins was measured 30 min after intravenous injection of radioiodinated rat very low density lipoprotein (VLDL) remnants, rat and human VLDL, low density lipoprotein (LDL) and high density lipoprotein (HDL). Using rat VLDL, VLDL-remnants, LDL and HDL, respectively, the non-parenchymal cells contain 4.7, 4.9, 6.1 and 5.3 times the amount of trichloroacetic acid-precipitable radioactivity per mg cell protein as compared to parenchymal cells. For human VLDL, LDL and HDL these values are 5.1, 12.0 and 5.9 respectively. 2. The abilities of homogenates of human liver, rat liver parenchymal cells and rat liver non-parenchymal cells to hydrolyze human and rat iodinated VLDL apoprotein were determined by measuring the amount of trichloroacetic acid-soluble (non-iodide) radioactivity liberated upon incubation at the optimal pH of 4.2. Non-parenchymal cells possess a 8--21-fold higher maximal capacity to degrade VLDL apoprotein per mg of cell protein than parenchymal cells. This factor is 5--6 for VLDL-remnant apoprotein degradation measured at low (suboptimal) apolipoprotein concentrations. 3. It is concluded that, in addition to parenchymal cells, the non-parenchymal cells play an important role in the hepatic uptake and possibly degradation of VLDL-(remnant) apoprotein.
D000818:Animals; D006207:Half-Life; D006801:Humans; D007263:Infusions, Parenteral; D007700:Kinetics; D008079:Lipoproteins, VLDL / Q000008:administration & dosage / Q000378:metabolism*; D008099:Liver / Q000378:metabolism*; D008297:Male; D051381:Rats
D008079:Lipoproteins, VLDL